Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?

Int J Hematol. 1994 Aug;60(2):145-9.

Abstract

A patient with secondary acute myelomonocytic leukemia after treatment with chronic oral etoposide (VP-16) for lung cancer is reported. The leukemic cells showed a t(9;11)(p22;q23) translocation. Southern blot analysis revealed the rearrangement of the MLL (ALL-1/HRX) gene at 11q23. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed a chimeric mRNA between the MLL gene at 11q23 and LTG9 (MLLT3/AF-9) gene at 9p22. The patient was successfully treated with a VP-16 based regimen. This case is instructive in the understanding of the leukemogenesis of VP-16-related leukemias.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Aged
  • Base Sequence
  • Carcinoma, Small Cell / drug therapy
  • Chromosomes, Human, Pair 11
  • Chromosomes, Human, Pair 9
  • Drug Administration Schedule
  • Etoposide / administration & dosage
  • Etoposide / adverse effects*
  • Genes / drug effects*
  • Humans
  • Leukemia, Myelomonocytic, Acute / chemically induced*
  • Leukemia, Myelomonocytic, Acute / genetics
  • Lung Neoplasms / drug therapy
  • Male
  • Molecular Sequence Data
  • Neoplasms, Second Primary / chemically induced*
  • Neoplasms, Second Primary / genetics
  • Polymerase Chain Reaction
  • Translocation, Genetic

Substances

  • Etoposide